Light Adjustable Lens (LAL), truly one of the great revolutions in modern cataract and lens surgery area.

Dr. Jay S. Pepose, Medical Director Pepose Vision Institute and Dr. Mujtaba A. Qazi – Co-Clinical investigator on the clinical trial, have started the Calhoun Vision Study, a new FDA clinical trial. This is the first light adjustable intraocular lens developed for cataract surgery. Pepose Vision Institute will be one of four sites in this study. The other locations are Los Angeles, CA. Kansas City, MO, and San Francisco., CA.

The unique feature of this lens implant, is that its power can be adjusted and fined tuned by applying light at a specific wavelength after it is already implanted into the eye. This may improve the accuracy of cataract surgery and make patients less dependent on glasses. There will be a special unit to change the power of the lens and lock it in (see attached slides and below). One slide is attached of the of the specially designed light adjustable silicone lens.

More than 3 million cataract surgeries are done each year in the US with up to 70 percent of the patients requiring glasses for optimal distance vision after the procedure. This is caused by a variety of factors such as wound healing changes, inaccuracies in pre-operative measurements or preexisting corneal astigmatism.

Everyone’s eyes are unique to each individual as a finger print. As a result each person will heal differently after surgery. With the Light Adjustable Lens, the vision correction is done AFTER the eye has healed.